Use the keywords feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#21
JOURNAL ARTICLE
Giselle Del Calvo, Celina M Pollard, Teresa Baggio Lopez, Jordana I Borges, Malka S Suster, Anastasios Lymperopoulos
INTRODUCTION: Nicotine is a major component of cigarette smoke with various detrimental cardiovascular effects, including increased oxidative stress in the heart. Agonism of α2 -adrenergic receptors (ARs), such as with dexmedetomidine, has been documented to exert cardioprotective effects against oxidative stress and related apoptosis and necroptosis. α2 -ARs are membrane-residing G protein-coupled receptors (GPCRs) that primarily activate Gi/o proteins. They are also subjected to GPCR-kinase (GRK)-2-dependent desensitization, which entails phosphorylation of the agonist-activated receptor by GRK2 to induce its decoupling from G proteins, thus terminating α2 AR-mediated G protein signaling...
2024: Drug Design, Development and Therapy
#22
REVIEW
Najam A Sharif
More than 75 million people worldwide suffer from ocular hypertension (OHT)-associated retinal and optic nerve degenerative diseases that cause visual impairment and can lead to blindness. In an effort to find novel pharmaceutical therapeutics to combat OHT with reduced side-effect potential, several emerging drug candidates have advanced to human proof-of-concept in recent years. One such compound is a nonprostaglandin (non-PG) EP2-receptor-selective agonist (omidenepag isopropyl ester). Omidenepag (OMD; free acid form) is a novel non-PG that selectively binds to and activates the human EP2-prostglandin receptor (EP2R) with a high affinity (Ki = 3...
January 1, 2024: Current Opinion in Pharmacology
#23
Guillermo Raul Vera-Duarte, Jesus Guerrero-Becerril, Carlos Adolfo Müller-Morales, Arturo Ramirez-Miranda, Alejandro Navas, Enrique O Graue-Hernandez
PURPOSE: To report a case of pressure-induced interlamellar stromal keratitis (PISK) 10 years after laser assisted in situ keratomileusis (LASIK). OBSERVATIONS: A case of a 36-year-old man who underwent LASIK and presented with PISK 10 years later. Before presenting to our department he consulted elsewhere for red eye, decreased visual acuity, foreign body sensation, and pain on the RE for 1 week. He was then prescribed topical prednisolone six times per day and was lost to follow-up...
December 2023: American Journal of Ophthalmology Case Reports
#24
JOURNAL ARTICLE
Shresthi Tripathi, Khushwant S Yadav
BACKGROUND: Increased intraocular pressure is a common symptom of glaucoma. In severe circumstances, it may result in loss of eyesight. Glaucoma treatment is difficult due to ocular physiological barriers that prevent medications from reaching the afflicted area. Traditional formulations (eye drops) have a short residence period and are rapidly drained away via the nasolacrimal duct, resulting in increased adverse drug responses and lower efficacy. The usage of nanoparticles such as niosomes could be one potential answer to these problems...
December 29, 2023: Daru: Journal of Faculty of Pharmacy, Tehran University of Medical Sciences
#25
JOURNAL ARTICLE
Thomas W Samuelson, Ticiana De Francesco, Iqbal Ike K Ahmed, Steven J Gedde, Vikram R Paranjpe, Kuldev Singh, Jacob W Brubaker, Davinder S Grover, Ronald L Fellman, Amy D Zhang, Keith Barton
A 70-year-old man had progressive and severe glaucoma in each eye. He was intolerant to dorzolamide, brimonidine, and netarsudil. Each eye had prior selective laser trabeculoplasty (SLT) as well as phacoemulsification plus minimally invasive glaucoma surgery (MIGS) 6 years before current presentation (iStent [Glaukos Corp.] in the right eye and Cypass [Alcon Laboratories, Inc.] in the left eye). Postoperative acuities were 20/20 and 20/25 in the right and left eyes, respectively. When his left eye progressed with loss of central acuity despite peak intraocular pressures (IOPs) in the middle to upper teens, neuro-ophthalmology consultation was obtained (Figure 1JOURNAL/jcrs/04...
January 1, 2024: Journal of Cataract and Refractive Surgery
#26
JOURNAL ARTICLE
Nana Takahashi, Kota Sato, Naoki Kiyota, Mai Yamazaki, Eriko Kunikane, Toru Nakazawa
PURPOSE: The purpose of this study was to investigate the effect of a 1% brinzolamide and 0.1% brimonidine fixed combination (BBFC) on ONH blood flow (BF) in rabbits. METHODS: A crossover study was conducted on pigmented rabbits; a physiological saline solution, brinzolamide, or BBFC was administered for eight days. ONH BF, intraocular pressure (IOP) and systemic parameters were measured before the eighth day's first dose and at 6, 9, 12, and 14 hours after the dose...
2023: PloS One
#27
REVIEW
Alessandra Boccaccini, Dario Cavaterra, Carmela Carnevale, Lucia Tanga, Stefano Marini, Alessio Bocedi, Pedro M Lacal, Gianluca Manni, Grazia Graziani, Diego Sbardella, Grazia Raffaella Tundo
In the last years, neuroprotective therapies have attracted the researcher interests as modern and challenging approach for the treatment of neurodegenerative diseases, aimed at protecting the nervous system from injuries. Glaucoma is a neurodegenerative disease characterized by progressive excavation of the optic nerve head, retinal axonal injury and corresponding vision loss that affects millions of people on a global scale. The molecular basis of the pathology is largely uncharacterized yet, and the therapeutic approaches available do not change the natural course of the disease...
November 23, 2023: Molecular Aspects of Medicine
#28
Rei Sakata, Shiro Mizoue, Keiji Yoshikawa, Misato Adachi, Shinji Ohkubo, Naoki Hamada, Tomoko Naito, Tomoyuki Muramatsu, Takeshi Hara, Ryo Asato, Makoto Aihara
No abstract text is available yet for this article.
November 22, 2023: Japanese Journal of Ophthalmology
#29
JOURNAL ARTICLE
Anusha Meesala, Ratikanta Tripathy, Harish Chandra Chaudhury, Jyoti Prakash Sahoo
BACKGROUND AND OBJECTIVES: Today, branded medications and polytherapy are frequently prescribed for glaucoma, even without giving the patient the proper instructions. Hence, the safety, effectiveness, cost, and patient compliance of glaucoma medication must be weighed, and the anti-glaucoma medicine usage must be studied. Analysis of glaucoma patients' prescription usage was the objective of this study. MATERIAL AND METHODS: Between January 2021 and February 2022, this prospective and observational study was carried out at Andhra Medical College in Vishakhapatnam...
October 2023: Curēus
#30
REVIEW
James Choe, John S Barbieri
Rosacea is a chronic inflammatory disease with a multifactorial pathogenesis. The wide spectrum of clinical phenotypes, including erythema, telangiectasia, inflammatory papules and pustules, and phyma, demand an individualized approach to treatment. This narrative review offers an updated reference for rosacea management by covering the latest developments in both topical and systemic treatments, including data from newly approved therapies, updates to current treatment modalities and ongoing clinical trials...
October 12, 2023: Dermatology and Therapy
#31
JOURNAL ARTICLE
Yakun Li, Qi Zhou
BACKGROUND: We report a case of uveal effusion in a nanophthalmic eye after topical use of brimonidine. CASE PRESENTATION: A 42-year-old male patient with nanophthalmos experienced sudden blurred vision in the right eye after using topical brimonidine when picking up tennis balls repeatedly 6 weeks after bilateral YAG peripheral iridotomy. Ocular examination showed wide choroidal and exudative retinal detachment in the temporal and inferior region, involving the macula...
October 9, 2023: BMC Ophthalmology
#32
JOURNAL ARTICLE
Eriko Kunikane, Yusuke Orii, Akiko Inoue, Masaru Inatani
INTRODUCTION: The factors related to the ocular penetration of drugs after the administration of eye drops in humans have not been examined in detail. Therefore, this study assessed the influence of patient factors on the intraocular penetration of eye drops. METHODS: A pooled analysis was performed on the data of 42 participants from three studies to evaluate the ocular pharmacokinetics in humans after the topical application of brimonidine-related eye drops. The patients were scheduled for vitrectomy and received brimonidine-related eye drops (0...
September 7, 2023: Ophthalmology and Therapy
#33
JOURNAL ARTICLE
Elena Montolío-Marzo, Rodrigo Fernández-Narros, Laura Morales-Fernández, Javier García-Bella, Federico Sáenz-Francés, Julián García-Feijoo, Jose María Martínez-de-la-Casa
OBJECTIVE: To compare objective ocular redness measured using OCULUS Keratograph 5 M before and after 0.2% brimonidine instillation in glaucoma patients under topical hypotensive treatment. METHODS: 60 eyes from 60 subjects diagnosed with glaucoma or ocular hypertension under hypotensive ocular topical treatment were analyzed. Basal Ophthalmological examination was performed.Outcome variables were OCULUS Keratograph 5 M redness scores (RS) before and after 0...
September 3, 2023: European Journal of Ophthalmology
#34
JOURNAL ARTICLE
Ajay J Khopade, Arindam Halder, Vivek Patel, Shivam Upadhyay, Vinod Burade, Bharat Pateliya, Satish Panchal, Sanjay Mandhane, Chandan Awati, Murlidhar Zope
Purpose: This article aims to describe a preclinical proof of concept for a novel once-a-day (OD) brimonidine ophthalmic nanosuspension. Methods: The preclinical proof of concept was established using New Zealand white rabbits as animal models. Dose-finding, multiple-dose efficacy, ocular pharmacokinetic, and hemodynamic studies were performed in normotensive rabbits. Steroid-induced ocular hypertension model in rabbits was used to study efficacy in glaucomatous pathophysiology. The test (0.35% OD suspension) and reference (0...
August 30, 2023: Journal of Ocular Pharmacology and Therapeutics
#35
JOURNAL ARTICLE
Xiaohui Wang, Rui Zhang, Bin Chen, Ting Zhang, Xinghua Jin, Ping Gao
BACKGROUND: Although brimonidine is currently used in the clinical treatment of glaucoma and rosacea, research of the deep sedative effect on animals after systemic administration is reported firstly and has shown promising results. METHODS: The median effective dose (ED50 ), the median lethal dose (LD50 ), and the therapeutic index of brimonidine for deep sedation and formalin stimulation assay were determined by various animal experiments. The effect of synergistic anesthesia in rabbits with brimonidine and chloral hydrate was preliminarily evaluated...
August 23, 2023: Fundamental & Clinical Pharmacology
#36
JOURNAL ARTICLE
Rei Sakata, Shiro Mizoue, Keiji Yoshikawa, Misato Adachi, Shinji Ohkubo, Naoki Hamada, Tomoko Naito, Tomoyuki Muramatsu, Takeshi Hara, Ryo Asato, Makoto Aihara
PURPOSE: A brimonidine tartrate 0.1%/brinzolamide 1% fixed-dose combination (BBFC) was recently approved for glaucoma and ocular hypertension treatment in Japan. We investigated the efficacy and safety of BBFC used concomitantly with prostaglandin analogs (PG) or a PG/beta-blocker fixed-dose combination (PG/beta FC). STUDY DESIGN: This was a prospective, open-label, multicenter study. PATIENTS AND METHODS: We enrolled Japanese patients with open-angle glaucoma...
August 19, 2023: Japanese Journal of Ophthalmology
#37
JOURNAL ARTICLE
Numan Eraslan, Osman Celikay
BACKGROUND: In this study, we aimed to assess the central corneal epithelial thickness (CET), central corneal stromal thickness (CST), and total central corneal thickness (CCT) thinning relationships with dry eye development monitoring and underestimated measurement of intraocular pressure (IOP) in primary open-angle glaucoma (POAG) patients treated with timolol, dorzolamide, and brimonidine. METHODS: This longitudinal cohort study included 106 patients with POAG...
July 28, 2023: Photodiagnosis and Photodynamic Therapy
#38
JOURNAL ARTICLE
Mengxuan Liu, Megumi Honjo, Reiko Yamagishi, Makoto Aihara
PURPOSE: We investigated whether hydrogen peroxide (H2 O2 )-induced oxidative stress causes human trabecular meshwork (HTM) cell dysfunction observed in open angle glaucoma (OAG) in vitro , and the effects of topical glaucoma medications on oxidative stress in HTM cells. METHODS: We used commercially available ophthalmic solutions of brimonidine, omidenepag isopropyl, and ripasudil in the study. HTM cells were exposed to H2 O2 for 1 h, with or without glaucoma medications...
July 19, 2023: Current Eye Research
#39
JOURNAL ARTICLE
Masaru Inatani, Yusuke Orii, Kentaro Iwasaki, Shogo Arimura, Hiromi Sunagawa, Minako Shiokawa, Kenji Inoue, Takuto Sakono, Takato Sakono, Rika Kuwamura, Akiko Yoshida, Junko Oi, Yasuaki Kuwayama, Kiyoshi Kano, Noriaki Kido, Akiko Matsuyama, Mineo Ozaki, Hideki Abe, Chizuru Inoue, Satoko Nakagawa, Kunihiro Musashi, Akiyasu Kanamori, Jinhee Lee, Shinichiro Otani, Ryota Aoki, Hirotaka Tanabe, Shunsuke Nakakura, Katsuyoshi Suzuki, Takeshi Sagara, Yoshiaki Saito, Motoyasu Sameshima, Mai Urahashi, Fumika Watanabe-Kitamura, Toshihiro Inoue, Fumie Kagaya, Yusuke Murai, Sotaro Mori, Kaori Ueda, Takuji Kurimoto, Yuko Yamada-Nakanishi, Makoto Nakamura, Takehiro Yamashita, Sosuke Ishiyama, Shinichi Manabe, Keiko Takaki, Ken Hayashi, Akiko Ishida, Aika Tsutsui, Kaoru Manabe, Masaki Tanito
INTRODUCTION: This multicenter, randomized, comparative, and investigator-masked crossover clinical trial sought to compare the efficacy and tolerability of fixed combinations of 0.1% brimonidine/0.5% timolol (BTFC) versus 1% dorzolamide/0.5% timolol (DTFC) as adjunctive therapies to prostaglandin analogues. METHODS: A total of 110 patients with open-angle glaucoma or ocular hypertension previously treated with prostaglandin analogue monotherapy were randomized to receive either BTFC or DTFC as adjunctive therapy for 8 weeks...
July 15, 2023: Advances in Therapy
#40
JOURNAL ARTICLE
Yusuke Orii, Eriko Kunikane, Yutaka Yamada, Masakazu Morioka, Kentaro Iwasaki, Shogo Arimura, Akemi Mizuno, Masaru Inatani
PURPOSE: To evaluate the concentrations of brimonidine and brinzolamide in the vitreous and aqueous humor after instillation of a 0.1% brimonidine tartrate and 1% brinzolamide fixed-combination ophthalmic suspension. METHODS: The present investigation involved patients with macular holes or idiopathic epiretinal membranes who were planning to undergo vitrectomy. One week prior to surgery, the patients received twice-daily topical treatment with 0.1% brimonidine tartrate and 1% brinzolamide fixed-combination ophthalmic suspension...
June 21, 2023: Journal of Clinical Medicine
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
